• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

ZEG Berlin GmbH

Zentrum für Epidemiologie und Gesundheitsforschung

  • Home
  • Expertise
    • Real-World Evidence
    • Non-interventional study design
    • Post-authorization safety studies
    • Post-authorization efficacy studies
    • Cohort studies
    • Case-control studies
    • Medical Devices
    • Data collection instruments
  • Services
    • RWE Services
    • Crisis Management
    • Consulting
    • Data Management and Biostatistics
    • Medical Writing
    • Study Management
    • Quality Assurance
    • Pharmacovigilance
  • Library & News
    • News/Conferences
    • Publications
  • PROs
    • Menopause Rating Scale
      • Menopause Rating Scale (MRS) – Languages
    • Aging Male Symptoms Scale
      • AMS – properties as an outcome measure
      • AMS – properties as a screening tool
    • Quality of Sexual Function Scale
      • Quality of Sexual Function Scale
    • Short Term Hormone Effect Scale
      • Short Term Hormone Effect Scale
    • Research team
  • About Us
    • Who We Are
      • Management Board
      • Executive Team
      • Project Management Team
    • History
    • Careers
    • Data Protection Information
  • Contact

Study Type: Prospective Cohort

Dinger Jürgen, Do Minh Thai, Early use effects on the risk of venous thromboembolism after initiation of oral contraceptive use. Eur J Contracept Reprod Health Care. 2010; 15;S1:43.
Dinger Jürgen, Bardenheuer Kristina, The risk of vaenous thromboembolism in users of a drospirenone-containing oral contraceptive with a 24-day regimen - results from the INAS-OC study. Fertility and Sterility. 2010; 94 suppl 1:S3.
Dinger Jürgen, Assmann Anita, Moehner Sabine, Do Minh Thai, Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study. J Fam Plann Reprod Health Care. 2010; 36(3):123-129.
Dinger Jürgen, Assmann Anita, Long-term active surveillance study for oral contraceptives (LASS): Impact of oral contraceptive use on the start of antihypertensive treatment. Pharmacoepidemiology and Drug Safety. 2010; 19:S232.
Assmann Anita, Heinemann Klaas, Dinger Jürgen, The safety of oral hormone replacement therapy: Interim results from the EURAS-HRT study. Pharmacoepidemiology and Drug Safety. 2010; 19:S31-32.
Dinger Jürgen, Barnett Clare, Moehner Sabine, Assmann Anita, Unintended pregnancies in women using intrauterine devices: Results from the EURAS-IUD study. Pharmacoepidemiology and Drug Safety. 2010; 19:S242.
Cronin Maureen, Schellschmidt Ilka, Dinger Jürgen, Rate of pregnancy after using drospirenone and other progestin-containing oral contraceptives Obstet Gynecol. 2009; Sep;114(3):616-22. 10.1097/AOG.0b013e3181b46f54.
Dennerstein L, Lehert P, Bäckström T, Heinemann Klaas, Premenstrual symptoms - severity, duration and typology: an international cross-sectional study Menopause International. 2009; Sep;15(3):120-6. 10.1258/mi.2009.009030.
Cronin Maureen, Schellschmidt Ilka, Dinger Jürgen, Rate of pregnancy after using drospirenone and other progestin-containing oral contraceptives Obstet Gynecol. 2009; 114(3):616-22. 0.1097/AOG.0b013e3181b46f54.
Heinemann Lothar A , Key findings of the IMPACT study. Gynaecology Forum. 2009; 14(3): 9-13..
Assmann Anita, Dinger Jürgen, Filonenko A, Do Minh Thai, Heinemann Lothar A , Impact of severe premenstrual disorders on work, daily life, social relations, and quality of life: preliminary results of a multinational follow-up study. Pharmacoepidemiol Drug Saf. 2008; 17: S116.
Dinger Jürgen, Assmann Anita, Kuehl-Habich D, Oral contraceptives and the risk of arrhythmia: final results from the EURAS-OC study. Pharmacoepidemiology and Drug Safety. 2008; 17: S260.
  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Go to Next Page »

sidebar

Search our Publications

sidebar-alt

Footer

ZEG Berlin

Berlin Center for Epidemiology and Health Research

Invalidenstraße 115
10115 Berlin
Germany

Contact Us

Expertise

  • Real-World Evidence
  • Non-interventional study design
  • Post-authorization safety studies
  • Post-authorization efficacy studies
  • Cohort studies
  • Case-control studies
  • Medical Devices
  • Patient Reported Outcomes (PROs)
  • Data collection instruments

Services

  • Crisis Management
  • Consulting
  • Data Management and Biostatistics
  • Medical Writing
  • Study Management
  • Quality Assurance
  • Pharmacovigilance

ENCePP

We are a partner centre of the ENCePP scientific network which is coordinated by the European Medicines Agency. We are dedicated to excellence in research by adhering to the ENCePP Guide on Methodological Standards and promoting scientific independence and transparency. We register studies in the ENCePP E-Register of Studies, a publicly accessible resource for the registration of pharmacoepidemiological and pharmacovigilance studies.

General Data Protection Regulation

With a view to the introduction of the GDPR/EUDSGVO we are glad to present our newupdated privacy policy . The updated description are stored under “about us” and then “privacy policy/GDPR”. Further translation for study participants will follow contemporary.

© 2011–2026 ZEG Berlin

Impressum

Website by Laura Yeffeth.